# Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

> **NCT03306589** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** Cantharidin
- **BIOLOGICAL:** Lipopolysaccharide
- **BIOLOGICAL:** Granulocyte-Macrophage Colony-Stimulating Factor
- **DRUG:** Saline Solution

## Key facts

- **NCT ID:** NCT03306589
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-11
- **Primary completion:** 2018-01-03
- **Final completion:** 2018-06-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03306589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03306589, "Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03306589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*